State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100037, China.
Theranostics. 2021 Jan 1;11(3):1046-1058. doi: 10.7150/thno.53326. eCollection 2021.
Acute myocardial infarction (AMI) is one of the leading causes of mortality around the world, and the inflammatory response plays a pivotal role in the progress of myocardial necrosis and ventricular remodeling, dysfunction and heart failure after AMI. Therapies aimed at modulating immune response after AMI on a molecular and cellular basis are urgently needed. Exosomes are a type of extracellular vesicles which contain a large amount of biologically active substances, like lipids, nucleic acids, proteins and so on. Emerging evidence suggests key roles of exosomes in immune regulation post AMI. A variety of immune cells participate in the immunomodulation after AMI, working together to clean up necrotic tissue and repair damaged myocardium. Stem cell therapy for myocardial infarction has long been a research hotspot during the last two decades and exosomes secreted by stem cells are important active substances and have similar therapeutic effects of immunomodulation, anti-apoptosis, anti-fibrotic and angiogenesis to those of stem cells themselves. Therefore, in this review, we focus on the characteristics and roles of exosomes produced by both of endogenous immune cells and exogenous stem cells in myocardial repair through immunomodulation after AMI.
急性心肌梗死(AMI)是全球范围内导致死亡的主要原因之一,炎症反应在心肌坏死和心室重构、心功能障碍及心力衰竭的进展中起着关键作用。因此,迫切需要针对 AMI 后基于分子和细胞水平的免疫反应进行治疗。外泌体是一类含有大量生物活性物质(如脂质、核酸、蛋白质等)的细胞外囊泡。越来越多的证据表明外泌体在 AMI 后免疫调节中起着关键作用。多种免疫细胞参与 AMI 后的免疫调节,共同清除坏死组织并修复受损的心肌。干细胞治疗心肌梗死在过去二十年一直是研究热点,而干细胞分泌的外泌体是重要的活性物质,具有与干细胞本身相似的免疫调节、抗细胞凋亡、抗纤维化和血管生成的治疗作用。因此,在本综述中,我们重点关注内源性免疫细胞和外源性干细胞产生的外泌体通过 AMI 后免疫调节在心肌修复中的特征和作用。
J Cardiovasc Transl Res. 2018-10-29
Front Immunol. 2019-3-29
Arch Physiol Biochem. 2023-10
Circ Res. 2014-1-17
Front Cardiovasc Med. 2025-8-15
Int J Legal Med. 2025-8-25
Front Med (Lausanne). 2025-5-8
Exploration (Beijing). 2024-5-30
Front Cardiovasc Med. 2025-2-13
Cell Death Discov. 2024-12-19
Rev Cardiovasc Med. 2024-11-4
Trends Pharmacol Sci. 2020-9
Int J Mol Sci. 2020-7-16
Materials (Basel). 2020-7-18
Am J Physiol Heart Circ Physiol. 2020-4-24